Company intelligence / Profile preview

Nanjing RegeneCore Biotech Co., Ltd.

Nanjing, Jiangsu Sheng, Chinaregenecore.com ↗

Ownership: Private
Development stage: Other

Overview

The company has multiple programs in clinical development. RC1416 has received IND approvals for atopic dermatitis and COPD indications. RT2831, a bispecific nanobody drug targeting blood tumor cells, received FDA IND approval in July 2024 and China clinical trial approval in September 2024. RJK-RT2831 is in Phase 1 for refractory acute myeloid leukemia.

Therapeutic areas: PulmonologyImmunologyDermatologyOncologyNeurology
Modalities: Nanobody (sdAb)Monoclonal antibodyBispecific antibody
Industry: Biotech

Drug pipeline

7 assets

RC1416

6 more assets in the full pipeline.

Beyond the preview

Go deeper on Nanjing RegeneCore Biotech Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing RegeneCore Biotech Co., Ltd..